The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites
- PMID: 2776819
- DOI: 10.1007/BF00637745
The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites
Abstract
We have compared in two separate studies the kinetics of ceftriaxone and cefotaxime in 8 cirrhotic patients with ascites and 8 control subjects after a single 20 min intravenous infusion of 1 g of each drug. The apparent volumes of distribution (Vz) were found to be significantly higher in cirrhotics than in control subjects (0.87, versus 0.49, l.kg-1, for cefotaxime and 0.23 versus 0.13 for ceftriaxone). The elimination kinetics of ceftriaxone were similar in the two groups. In contrast, the total and non-renal clearances of cefotaxime were reduced in cirrhotic patients. The two drugs rapidly entered the ascitic fluid. Peritoneal concentrations of ceftriaxone were higher than 7 micrograms.ml-1 from the second hour after the infusion and were 8.9 micrograms.ml-1 at 24 h. Peritoneal concentrations of cefotaxime were higher than 4 micrograms.ml-1 from 0.5 to 8 h after the infusion.
Similar articles
-
[Pharmacokinetics of cefotaxime in cirrhotic patients with or without ascites].Presse Med. 1988 Dec 10;17(44):2331-4. Presse Med. 1988. PMID: 2974968 French.
-
Pharmacokinetics and ascitic fluid penetration of piperacillin in cirrhosis.Fundam Clin Pharmacol. 1991;5(9):789-95. doi: 10.1111/j.1472-8206.1991.tb00768.x. Fundam Clin Pharmacol. 1991. PMID: 1794834
-
Pharmacokinetics of ceftriaxone and its relation to concentrations in extravascular compartments. Comparison with cefotaxime.Chemotherapy. 1985;31(2):85-94. doi: 10.1159/000238319. Chemotherapy. 1985. PMID: 3987394
-
Differences between ceftriaxone and cefotaxime: microbiological inconsistencies.Ann Pharmacother. 2008 Jan;42(1):71-9. doi: 10.1345/aph.1H620. Epub 2007 Dec 19. Ann Pharmacother. 2008. PMID: 18094350 Review.
-
Pharmacokinetic profile of ceftriaxone in man.Am J Med. 1984 Oct 19;77(4C):17-25. Am J Med. 1984. PMID: 6093513 Review.
Cited by
-
Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.Drugs. 2002;62(7):1041-89. doi: 10.2165/00003495-200262070-00005. Drugs. 2002. PMID: 11985490 Review.
-
Management of antimicrobial use in the intensive care unit.Drugs. 2012 Mar 5;72(4):447-70. doi: 10.2165/11599520-000000000-00000. Drugs. 2012. PMID: 22303918 Review.
-
Clearance of ceftriaxone in critical care patients with acute renal failure.Intensive Care Med. 1990;16(7):448-53. doi: 10.1007/BF01711224. Intensive Care Med. 1990. PMID: 2269714
-
Clinical pharmacokinetics of newer antibacterial agents in liver disease.Clin Pharmacokinet. 1993 Jan;24(1):46-58. doi: 10.2165/00003088-199324010-00004. Clin Pharmacokinet. 1993. PMID: 8448972 Review.
-
Bacterial growth and ceftriaxone activity in individual ascitic fluids in an in vitro model of spontaneous bacterial peritonitis.Front Pharmacol. 2023 Mar 29;14:1124821. doi: 10.3389/fphar.2023.1124821. eCollection 2023. Front Pharmacol. 2023. PMID: 37063261 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources